Vaccine-Preventable Diseases
32
3
7
19
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 32 trials
100.0%
+13.5% vs benchmark
22%
7 trials in Phase 3/4
21%
4 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (32)
Hashtag HPV: HPV Vaccine Twitter Education Program
Culturally Tailored HPV Psychoeducational Multimedia Intervention
Maternal Immunization With Tetanus Toxoid, Reduced Diphtheria Toxoid, Reduced-dose (2 µg) Recombinant Pertussis Vaccine (TdaP2gen) and Its Effect on the Immune Response in Thai Infants up to 15-18 Months Old
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV
Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents
Game-Based Intervention to Promote HPV Vaccination
Playing Game to Learn About Children's Vaccine Project
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents
Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836
Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.
Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening
Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents
Herpes Virus Infections in Kidney Transplant Patients
Vaccine Hesitancy in Patients with Solid Tumors: a Cross-sectional Single-center Survey